4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies

Lee, J.; Lee, E. N.; Kim, E. Y.; Lee, H. J.; Park, H. J.; Sun, Chao; Lee, S. K.; Joh, Jae‐Won; Lee, Kwang‐Woong; Kwon, Ghee-Young; Kim, S. J.

doi:10.1016/j.transproceed.2005.01.016

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to monoclonal antibody targeting of CD4 during donor-specific transfusion pretreatment, generation of Treg has been achieved in vivo by blocking other cell surface signaling molecules, such as CD154, lymphocyte function-associated antigen 1 (LFA-1), inter-cellular adhesion molecule 1 (ICAM-1), and 4-1BB, at the time of donoralloantigen delivery (65,66). This suggests that modifying signals mediated by many surface proteins can promote Treg development at the time of antigen encounter.…”

Section: Generating Treg In Vivomentioning

confidence: 99%

Regulatory T Cells in Transplantation: Transferring Mouse Studies to the Clinic

Long

Wood

2009

Transplantation

View full text Add to dashboard Cite

Switching the balance from rejection of major histocompatibility-mismatched grafts toward long-term tolerance of donor grafts, with the need for minimal immunosuppressive drugs, is a major transplantation goal. Regulatory T cells (Treg) can induce and maintain antigen-specific immune tolerance and facilitate allogeneic graft survival successfully in animals. This review will focus on the valuable insights experimental mouse models have given us into the effects of currently used immunosuppressive reagents on Treg, the Treg transcription factor forkhead box P3, and strategies to expand or induce alloantigen-reactive Treg in vivo and in vitro. These have facilitated the translation of strategies for promoting transplantation tolerance towards a new clinical era.

show abstract

Section: Generating Treg In Vivomentioning

confidence: 99%

Regulatory T Cells in Transplantation: Transferring Mouse Studies to the Clinic

Long

Wood

2009

Transplantation

View full text Add to dashboard Cite

show abstract

“…As well as mAb targeting of CD4 during DST pre-treatment, generation of Tregs has been achieved in vivo by blocking other molecules such as CD154, LFA-1, ICAM-1 CTLA4 and 4-1BB, at the time of donoralloantigen delivery (40,41). This suggests that modifying signals mediated by these surface molecules can promote Treg development.…”

Section: Strategies For Generating T Regs In Vivomentioning

confidence: 99%

Regulatory T cells - a journey from rodents to the clinic

Long

Wood²

2007

Front Biosci

View full text Add to dashboard Cite

Over the past decade our understanding about a subset of T lymphocytes, now termed regulatory T cells (Tregs) and previously known as suppressor T cells, has increased immensely. Tregs can induce and maintain immune tolerance and have the capacity to facilitate antigen-specific long-term graft survival successfully in animals receiving allogeneic organ transplants. The development of approaches to generate alloantigen reactive Tregs would provide an exciting and effective adjunct or alternative therapy to the life-long program of immunosuppression currently necessary to prevent graft rejection in the clinical setting. This review will focus on how rodent experimental models have helped us to figure out how Tregs could be induced in humans and harnessed to enable long-term transplant acceptance.

show abstract

Combination of targeted therapy and immunotherapy in melanoma

Blank

Hooijkaas

Haanen

et al. 2011

Cancer Immunol Immunother

View full text Add to dashboard Cite

The treatment of human melanoma has progressed markedly in recent years. Building on the observation that immune recognition is a frequent event in melanoma, a series of immunotherapeutic approaches have been evaluated in clinical trials, culminating in the first phase III study improving overall survival of melanoma patients since 20 years. However, the response rates seen upon immunotherapeutic interventions such as anti-CTLA4 treatment are often low. Furthermore, clinical responses can take several weeks to develop, during which time stage IV melanoma patients often deteriorate. Recent advances in our understanding of the genetic lesions in human melanoma now also allow the specific targeting of the signaling pathway alterations in this disease. Such targeted therapies can lead to high response rates, although the duration of these responses is thus far relatively short. We suggest that the combination of immuno and targeted therapy offers potential for synergy for both conceptual and practical reasons. In this review, we will discuss the potential and possible limitations for such combination therapy, and we describe the most promising combinations of targeted therapy and immunotherapy that can be tested in the clinic in the coming years. The concept of induction therapy by small molecule administration and consolidation by immunotherapeutics also has potential for the treatment of other human cancers.

show abstract

4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies

Cited by 4 publications

References 7 publications

Regulatory T Cells in Transplantation: Transferring Mouse Studies to the Clinic

Regulatory T Cells in Transplantation: Transferring Mouse Studies to the Clinic

Regulatory T cells - a journey from rodents to the clinic

Combination of targeted therapy and immunotherapy in melanoma

Contact Info

Product

Resources

About